Kazia Therapeutics continues to make good progress on cancer treatment assets
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) is making good progress with its two pipeline assets, paxalisib and EVT801, with the latter having cleared third dose level and is recruiting well. The ...